Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274755 | 0.87 | GRM5 (0.44) | GRM5IRAK4NOTUMADORA2ADRD2 | |
| SCHEMBL12474195 | 0.81 | LMNA (0.43) | GRM5CACNA2D1 | |
| SCHEMBL161006 | 0.80 | PARP1 (0.33) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL12474193 | 0.78 | KDM4E (0.40) | GRM5 | |
| SCHEMBL15041958 | 0.78 | PARP1 (0.33) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL163952 | 0.78 | PARP1 (0.44) | GRM5 | |
| SCHEMBL163957 | 0.77 | MET (0.43) | GRM5MAPK10 | |
| SCHEMBL13274914 | 0.76 | PARP1 (0.37) | GRM5NOTUMADORA2ACYP11B1CYP11B2 | |
| SCHEMBL15041955 | 0.76 | PARP1 (0.46) | GRM5ADORA2A | |
| SCHEMBL255608 | 0.76 | ALK (0.36) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| WO-2012030633-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MET, ABL1, ERBB2 | GRM5 1037/4885IRAK4 674/4885NOTUM 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.